Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good wordor the badfrom your shop to Eric Sagonowsky (email) or Angus Liu (email), and we will feature it here at the end of each week.

Grail Elizabeth Mansfield became head of regulatory strategy.

Elizabeth Mansfield, Ph.D., the deputy director in charge of personalized medicine at FDAs Office of In Vitro Diagnostics and Radiological Health, has left the agency and joined liquid biopsy startup Grail. She joined the agency in 2006 and played a major role in advancing regulations for precision medicine and next-generation sequencing. She is now head of regulatory strategy at Grail, an Illumina spinoff, which secured over $100 million in Series Aand is looking to raise $1 billion in Series B. Jeffrey Huber, who formerly ran Googles Geo division including Google Maps and Google Earth, is currently the companys CEO. Genomeweb story | Read more on FierceMedicalDevices

PureTech Atul Pande was named CMO.

After recruiting Modernas Joseph Bolen, Ph.D., as its CSO last October, PureTech Healthjust added Atul Pande, M.D., as its CMO. Formerly SVP and head of neurosciences at GlaxoSmithKline, Pande brings with him more than two decades of experience in drug R&D. In this new role, Dr. Pande will oversee all clinical operations across PureTech Healths pipeline, which include several treatments for neurological disorders like ADHD, Alzheimers and schizophrenia. Other areas the companys been focusing on include immune and gastrointestinal systems. The company boasts its approach to R&D as addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. Release

Veterinary company Zomedica creates new EVP position

Zomedica Robert DiMarzo was appointed EVP of global strategy.

Robert DiMarzo has joined Zomedica in the companys newly created role of EVP of global strategy, responsible for expanding the animal health experts business outside of North America. DiMarzo has more than 25 years of experience in the animal health industry, having held several leadership roles, including Henry Scheins VP of commercial development and product category management with the global animal health group, and several director-level and executive positions at Pfizers animal health businesses (now Zoetis). Release

>Symbiomix Therapeutics hired David Stern as CEO, hard on the heels of the company's NDA submission to the FDA for antibioticcandidate Solosec. Release

>Catabasis Pharmaceuticals promoted Ted Hibben, previously SVP of corporate development, to CBO. Release

>CRO Celerion appointedMarc Hoffman, M.D., as CMO. Release

>Intercept, with its 2016 financial report, announced the appointment of 23-year Sanofi vet Jerry Durso as COO. Release

>BioAmber CEO Jean-Francois Huc resigned for personal reasons, and Fabrice Orecchioni, the company's COO, has succeeded him.Release

>Endocyte, which focuses ondeveloping targeted small-molecule drug conjugates and companion imaging agents, put 16-year Eli Lilly vet Michael T. Andriole in the role of CFO. Release

> Peter G. Smith, Ph.D., will become the CSO of Eisai's H3 Biomedicine, which specializesinprecision medicines for oncology. Release

>CRO Pharm-Olam namedJulia Graz as senior director ofbiostatistics. Release

> Harpoon Medical hired structural heart expert Laura Brenton as VP of clinical affairs. Release

Continue reading here:

Chutes & Ladders: FDA's personalized medicine head leaves for Grail - FierceBiotech